1. ALLA AKTIER
  2. NYHETER
  3. PROSTALUND

ProstaLund

Nyheter ProstaLund Nyheter alla bolag

A stable quarter with growth and new agreements

MAR

1 July-30 September

  • Net sales reached SEK 3,8 (3,7) million
  • Loss after taxes SEK -2,1 (-1,7) million
  • Earnings per share were SEK -0,04 SEK (-0,03)
  • Cash and equivalents were 15,9 (16,7) million

Significant events during period

  • The company carried out a rights issue which brought the company approximately SEK 19.8 million in capital before issue costs
  • A letter of intent regarding the distribution agreement for China is signed
  • Agreement with Capio Specialistmottagning, Lund
  • Distribution agreement signed for Brazil

1 January-30 September

  • Net sales reached SEK 11,9 (12,1) million
  • Loss after taxes SEK -8,0 (-5,7) million
  • Earnings per share were SEK -0,15 SEK (-0,12)

Significant events after the end of the period

  • Results for the registry study on prostate cancer are presented at the Urologidagarna in Malmö by one of the authors
  • Distribution agreement signed for Spain
Key figures



(SEK MILLION)Jan-Sep
2022		Jan-Sep
2021		Jan-Sep
2020		Jan-Sep
2019
Net sales11,912,18,89,5
Gross margin, %77857167
Operating profit/loss-7,7-5,6-6,2-8,1
Cash flow from operating activities-13,0-6,3-6,2-6,6
Average number of employees7755

“There is no longer any doubt that we have world-class products”

Johan Wennerholm
CEO, ProstaLund AB (publ)

Please see attached PDF for full report.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

This information is information that ProstaLund AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-10-21 08:15 CEST.

Attachments

ProstaLund AB (publ) Delårsrapport Jan Sep 2022 ENG

Datum 2022-10-21, kl 08:15
Källa MFN
Bifogade filer
ProstaLund AB (publ) Delårsrapport Jan Sep 2022 ENG
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!